2022 Year in Review - Multiple Myeloma
Implementation of a pharmacist on the healthcare team can have significant clinical and economic benefits. Read More ›
Updated results from a phase 1 trial of subcutaneous isatuximab via OBDS continue to demonstrate an excellent local tolerability with comparable efficacy. Read More ›
Preliminary data support the use of BMS-986393 in patients with RRMM despite prior BCMA-directed therapy. Read More ›
Data from a subgroup analysis of CANDOR supported the efficacy of daratumumab plus carfilzomib and dexamethasone in RRMM, even in high-risk patients. Read More ›
A phase 1 trial of GC012F demonstrated an overall response rate of 100% in high-risk, transplant-eligible patients with newly diagnosed multiple myeloma. Read More ›